Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Fuji Pharma Extend Biosimilar Partnership in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"}]

Alvotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alvotech and Fuji Pharma Extend Biosimilar Partnership in Japan

Details:

The companies have announced extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. The initial pipeline contains biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan.

Lead Product(s): Monoclonal antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Fuji Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership December 16, 2020

ASK
US

Upload
your Pipeline Activity

Alvotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Details:

Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S.

Lead Product(s): Monoclonal Antibodies biosimilar

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 05, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY